Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges
Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in t...
Saved in:
Published in | Current HIV/AIDS reports Vol. 17; no. 1; pp. 26 - 34 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
New York
Springer US
01.02.2020
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Purpose of Review
The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.
Recent Findings
Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART.
Summary
Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation. |
---|---|
AbstractList | The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.PURPOSE OF REVIEWThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation.RECENT FINDINGSContinuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation. The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years. Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation. Purpose of ReviewThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years.Recent FindingsContinuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART.SummaryGreat progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation. Purpose of Review The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led to dramatic increases in antiretroviral therapy (ART) coverage among HIV-infected Chinese patients. Despite limitations in the number of available free antiretroviral drugs, the overall mortality associated with HIV/AIDS has dropped from 39.3 per 100 person-years in 2002 to 3.1 in 2014. In this review, we summarize the challenges, responses, and achievements of antiretroviral therapy (ART) in China over the past 20 years. Recent Findings Continuous optimization of the Chinese National Guidelines for HIV/AIDS Diagnosis and Treatment has been guided by data from serial domestic multi-center studies aimed at evaluating efficacy and toxicity of available ART regimens among Chinese patients with HIV, with the goal of maximizing adherence, access, and efficacy. In addition, increasing attention has been focused on the importance of continuity in the HIV care cascade to promote linkage to care, and address the multidisciplinary chronic care needs HIV/AIDS patients on lifelong ART. Summary Great progress has been achieved in the past 20 years in terms of access to and optimization of antiretroviral treatment in China. As the number of patients receiving long-term ART continues to grow, the focus of HIV/AIDS treatment has gradually transitioned from urgent care to the management of non-AIDS-related chronic complications and control of chronic inflammation. |
Author | Hsieh, Evelyn Cao, Wei Li, Taisheng |
Author_xml | – sequence: 1 givenname: Wei surname: Cao fullname: Cao, Wei organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences – sequence: 2 givenname: Evelyn surname: Hsieh fullname: Hsieh, Evelyn organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Section of Rheumatology, Department of Internal Medicine, Allergy and Immunology, Yale School of Medicine – sequence: 3 givenname: Taisheng surname: Li fullname: Li, Taisheng email: litsh@263.net organization: Department of Infectious Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31939111$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kc1OGzEUha2KqkDoC3RRWeqmmyn22Jmxu6gUhVIiISGV0K3leO4kpjN2sD38PT1OA7RlwcpX9neOzvXZRzvOO0DoAyVfKCH1YaRUEl4QKgtCeC2K2zdoj465KNi4rnae50rsov0YLwlhXPLqHdplVDJJKd1Dv8_Wyfb23rolngfQqQeXcOsDnjRDlyK-sWmFT2a_Diezo3NsHZ6urNNf8flgDMQIEftrCHh-4_ERGN3kC-0a_BN6bd3GdbrSXQduCfEAvW11F-H94zlCF8ff59OT4vTsx2w6OS0Mr3kqFlzoqqTaUCDcmEVtNBmTRgKVeeB1y-tGEA6iAWo0ZKwq27YVJSMVBSHYCH3b-q6HRQ-NyRsF3al1sL0Od8prq_5_cXallv5aVVJITuts8PnRIPirAWJSvY0Guk478ENUJWNCSrn5xRH69AK99ENweb1McVFWjMkyUx__TfQc5amHDIgtYIKPMUCrjE06Wb8JaDtFidpUrraVq1y5-lO5us3S8oX0yf1VEduKYoZzN-Fv7FdUD-t-v1k |
CitedBy_id | crossref_primary_10_1007_s12144_025_07419_5 crossref_primary_10_1186_s12879_024_09065_x crossref_primary_10_1097_QAI_0000000000003053 crossref_primary_10_1186_s12879_021_06644_0 crossref_primary_10_1371_journal_pone_0238564 crossref_primary_10_1002_jmv_29824 crossref_primary_10_1007_s11657_021_00890_0 crossref_primary_10_3389_fpubh_2022_1056915 crossref_primary_10_1111_jcmm_17534 crossref_primary_10_3389_fpubh_2024_1485516 crossref_primary_10_2147_DDDT_S369832 crossref_primary_10_3389_fphar_2023_1268597 crossref_primary_10_1186_s12879_025_10703_1 crossref_primary_10_1186_s12981_024_00682_9 crossref_primary_10_1017_S2045796023000240 crossref_primary_10_1097_CM9_0000000000002918 crossref_primary_10_3390_v16111713 crossref_primary_10_1097_CM9_0000000000001824 crossref_primary_10_2174_1570162X19666210910144433 crossref_primary_10_3390_ijerph19105910 crossref_primary_10_1093_infdis_jiae302 crossref_primary_10_1186_s12879_022_07113_y crossref_primary_10_3389_fpubh_2022_800839 crossref_primary_10_1186_s12889_024_20728_x crossref_primary_10_3389_fmicb_2020_604993 crossref_primary_10_2147_DDDT_S406255 crossref_primary_10_3389_fphar_2020_00800 crossref_primary_10_1097_QAI_0000000000003047 crossref_primary_10_1007_s40121_023_00877_z crossref_primary_10_1007_s10508_021_02155_w crossref_primary_10_1016_j_ijnss_2023_06_003 crossref_primary_10_1002_cpdd_1309 crossref_primary_10_1099_jmm_0_001949 crossref_primary_10_1097_CM9_0000000000003317 crossref_primary_10_1097_CM9_0000000000003202 crossref_primary_10_3390_ijms21030748 crossref_primary_10_1002_ijc_35242 crossref_primary_10_1186_s12879_024_09624_2 crossref_primary_10_1089_apc_2022_0192 crossref_primary_10_1186_s12944_024_02224_8 crossref_primary_10_1186_s12981_024_00680_x crossref_primary_10_12677_tcm_2024_1311441 crossref_primary_10_1093_jac_dkad370 crossref_primary_10_2196_42469 crossref_primary_10_1097_NJH_0000000000000824 crossref_primary_10_1093_ve_veab094 crossref_primary_10_1038_s41598_024_80749_9 crossref_primary_10_1097_CM9_0000000000002500 crossref_primary_10_1186_s12879_023_08359_w crossref_primary_10_1080_07853890_2024_2427910 crossref_primary_10_3389_fpubh_2022_902537 crossref_primary_10_3390_ijerph191610220 crossref_primary_10_1111_hiv_13252 crossref_primary_10_1186_s12953_024_00230_3 crossref_primary_10_1186_s12903_023_03752_y crossref_primary_10_1089_aid_2020_0273 crossref_primary_10_1016_j_jgar_2022_01_017 crossref_primary_10_1016_S2352_3018_21_00316_7 crossref_primary_10_1136_sextrans_2021_055019 crossref_primary_10_3389_fonc_2023_1248790 crossref_primary_10_3390_vaccines11050921 crossref_primary_10_2147_IJWH_S374976 crossref_primary_10_1016_j_jot_2021_04_002 crossref_primary_10_3389_fimmu_2023_1153790 crossref_primary_10_2174_1570162X21666230524141239 crossref_primary_10_1016_j_watres_2021_117803 crossref_primary_10_1371_journal_pone_0284405 crossref_primary_10_3389_fpubh_2022_1054765 crossref_primary_10_4103_jehp_jehp_126_23 crossref_primary_10_1186_s12888_022_04366_4 crossref_primary_10_12677_ACM_2023_1371557 crossref_primary_10_1111_hiv_13758 crossref_primary_10_3389_fcimb_2023_1249837 crossref_primary_10_1080_21505594_2024_2373105 crossref_primary_10_3389_fmed_2022_965836 crossref_primary_10_1016_j_jgar_2023_01_002 crossref_primary_10_1007_s10461_024_04420_0 crossref_primary_10_1093_ofid_ofab309 crossref_primary_10_1371_journal_pgph_0000956 crossref_primary_10_1038_s41467_023_41051_w crossref_primary_10_3390_ph17010115 crossref_primary_10_1016_j_jinf_2021_12_034 crossref_primary_10_1007_s00198_020_05584_w crossref_primary_10_1016_S2666_7568_22_00003_4 crossref_primary_10_5812_archcid_145233 crossref_primary_10_1177_09564624241283983 crossref_primary_10_1097_MD_0000000000023638 crossref_primary_10_1097_CM9_0000000000002939 crossref_primary_10_1186_s12985_023_02193_x crossref_primary_10_1089_apc_2024_0045 crossref_primary_10_1097_CM9_0000000000001447 crossref_primary_10_1097_CM9_0000000000002898 crossref_primary_10_1016_j_scitotenv_2023_162589 crossref_primary_10_1097_CM9_0000000000003358 crossref_primary_10_1186_s12981_024_00678_5 crossref_primary_10_1007_s15010_020_01508_2 crossref_primary_10_1093_cid_ciaa835 crossref_primary_10_1016_j_jiac_2021_02_003 |
Cites_doi | 10.1001/jamainternmed.2013.3728 10.7326/0003-4819-151-4-200908180-00005 10.1086/649215 10.1111/imr.12065 10.1097/COH.0000000000000230 10.1186/s12879-016-1928-x 10.1056/NEJMoa1506816 10.1038/nrneph.2015.9 10.7448/IAS.19.1.20659 10.1016/S1473-3099(14)70946-6 10.1093/cid/cir552 10.1038/s41598-018-29202-2 10.1371/journal.pone.0165110 10.1111/hiv.12171 10.1097/QAI.0b013e3182845cc7 10.1111/hiv.12421 10.1097/QAI.0b013e3181ba1c31 10.1186/1471-2210-4-2 10.1371/journal.pone.0047289 10.1186/s12879-018-3158-x 10.1007/s00705-018-3839-1 10.1111/nep.12031 10.1097/QAD.0b013e32801022eb 10.1179/1528433614Z.0000000005 10.1038/sj.cr.7290362 10.1097/01.aids.0000304710.10036.2b 10.1097/QAD.0000000000000125 10.1371/journal.pone.0182335 10.1016/S0140-6736(13)62187-X 10.1002/art.10411 10.1093/cid/ciu086 10.1097/QAD.0b013e328355ced2 10.3760/cma.j.issn.0366-6999.20132557 10.1097/QAI.0000000000000927 10.1371/journal.pone.0003918 10.1016/S1473-3099(15)70060-5 10.1111/hiv.12607 10.1136/annrheumdis-2013-204807 |
ContentType | Journal Article |
Copyright | The Author(s) 2020 This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
Copyright_xml | – notice: The Author(s) 2020 – notice: This work is published under https://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
DBID | C6C AAYXX CITATION NPM K9. 7X8 5PM |
DOI | 10.1007/s11904-019-00478-x |
DatabaseName | Springer Nature OA Free Journals CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed ProQuest Health & Medical Complete (Alumni) |
Database_xml | – sequence: 1 dbid: C6C name: Springer Nature OA Free Journals url: http://www.springeropen.com/ sourceTypes: Publisher – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Public Health |
EISSN | 1548-3576 |
EndPage | 34 |
ExternalDocumentID | PMC6989417 31939111 10_1007_s11904_019_00478_x |
Genre | Journal Article Review |
GeographicLocations | China |
GeographicLocations_xml | – name: China |
GrantInformation_xml | – fundername: NCATS NIH HHS grantid: UL1 TR001863 |
GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 1N0 203 29F 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2VQ 2~H 30V 4.4 406 408 40D 40E 5GY 5VS 6J9 6NX 875 8UJ 95- 95. 95~ 96X AAAVM AABHQ AACDK AAHNG AAIAL AAJBT AAJKR AANXM AANZL AARHV AARTL AASML AATNV AATVU AAUYE AAWCG AAYIU AAYQN AAYTO AAYZH ABAKF ABDZT ABECU ABFTV ABHQN ABJNI ABJOX ABKCH ABMNI ABMQK ABNWP ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABWNU ABXPI ACAOD ACDTI ACGFS ACHSB ACHXU ACKNC ACMDZ ACMLO ACOKC ACOMO ACPIV ACPRK ACREN ACSNA ACZOJ ADHHG ADHIR ADINQ ADKNI ADKPE ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEBTG AEFQL AEGAL AEGNC AEGXH AEJHL AEJRE AEKMD AEMSY AENEX AEOHA AEPYU AESKC AETLH AEVLU AEXYK AFBBN AFLOW AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGJBK AGMZJ AGQEE AGQMX AGRTI AGWIL AGWZB AGYKE AHAVH AHBYD AHSBF AHYZX AIAKS AIGIU AIIXL AILAN AITGF AJBLW AJRNO AJZVZ ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ AXYYD B-. BA0 BDATZ BGNMA C1A C6C CAG COF CS3 CSCUP CUW DDRTE DNIVK DPUIP EBD EBLON EBS EIOEI EJD EMOBN ESBYG F5P FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 H13 HF~ HG6 HMJXF HRMNR HZ~ IJ- IKXTQ IWAJR IXC IXD IXE I~Z J-C JBSCW JZLTJ KOV LLZTM M4Y MA- NPVJJ NQJWS NU0 O9- O9J P9S PF0 PT4 QOR QOS R89 R9I ROL RPX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TUC U2A U9L UG4 UOJIU UTJUX UZXMN VC2 VFIZW W48 WK8 YLTOR Z7U ZMTXR ZOVNA ~A9 AAPKM AAYXX ABBRH ABDBE ABFSG ACMFV ACSTC AEZWR AFDZB AFHIU AFOHR AHPBZ AHWEU AIXLP ATHPR AYFIA CITATION NPM ABRTQ K9. 7X8 5PM |
ID | FETCH-LOGICAL-c474t-b48a621ac1e04ccb7ca050d9e19a0547f47d804e8de1caec1e62fff823061e883 |
IEDL.DBID | U2A |
ISSN | 1548-3568 1548-3576 |
IngestDate | Thu Aug 21 18:20:45 EDT 2025 Fri Jul 11 08:28:39 EDT 2025 Fri Jul 25 09:58:09 EDT 2025 Wed Feb 19 02:30:56 EST 2025 Tue Jul 01 01:53:31 EDT 2025 Thu Apr 24 23:00:54 EDT 2025 Fri Feb 21 02:29:52 EST 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | Continuum of care Highly active antiretroviral therapy National Free Antiretroviral Treatment Program Human immunodeficiency virus Acquired immune deficiency syndrome Multidisciplinary care |
Language | English |
License | Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-b48a621ac1e04ccb7ca050d9e19a0547f47d804e8de1caec1e62fff823061e883 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
OpenAccessLink | https://link.springer.com/10.1007/s11904-019-00478-x |
PMID | 31939111 |
PQID | 2348263392 |
PQPubID | 2044209 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6989417 proquest_miscellaneous_2338999319 proquest_journals_2348263392 pubmed_primary_31939111 crossref_citationtrail_10_1007_s11904_019_00478_x crossref_primary_10_1007_s11904_019_00478_x springer_journals_10_1007_s11904_019_00478_x |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2020-02-01 |
PublicationDateYYYYMMDD | 2020-02-01 |
PublicationDate_xml | – month: 02 year: 2020 text: 2020-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationTitle | Current HIV/AIDS reports |
PublicationTitleAbbrev | Curr HIV/AIDS Rep |
PublicationTitleAlternate | Curr HIV/AIDS Rep |
PublicationYear | 2020 |
Publisher | Springer US Springer Nature B.V |
Publisher_xml | – name: Springer US – name: Springer Nature B.V |
References | Lv, Zhang, Shi, Zheng, Li, Chen, Wu, Jiang, Li, Gong (CR46) 2015; 74 Zhang, Pan, Yu, Wen, Zhao (CR3) 2005; 15 Zhang, Liu, Sun, Sun, Lu (CR37) 2017; 12 (CR26) 2017; 10 Klatt, Chomont, Douek, Deeks (CR41) 2013; 254 Guo, Cheng, Hsieh, Du, Fu, Peng, Li, Song, Routy, Li (CR11) 2018; 19 Carey, Puls, Amin, Losso, Phanupak, Foulkes, Mohapi, Crabtree-Ramirez, Jessen, Kumar (CR10) 2015; 15 Wu, Norris, Liu, Li, Su, Zhu, Wang (CR40) 2014; 27 (CR14) 2015; 8 Xu, Peng, Peng, Ji, Chen, Wang, Lu, Xie, Sun, Wang, Wu (CR38) 2018; 163 (CR9) 2014; 383 Zhang, Haberer, Wang, Zhao, Ma, Zhao, Yu, Goosby (CR4) 2007; 21 (CR7) 2011; 29 Li, Chang, Han, Zhuang, Li, Liu, Liu, Bao, Zhang, Song (CR35) 2016; 16 Massanella, Fromentin, Chomont (CR43) 2016; 11 Li, Han, Xie, Gu, Li, Wang, Lv, Song, Li, Routy, Ishida, Iwamoto, Li (CR17) 2014; 28 CR2 Zhang, Zhu, Wu, Dou, Zhang, Kleinman, Bulterys, Wu, Ma, Zhao, Liu, Fang, Liu, Cai, Shang (CR28) 2014; 14 Li, Guo, Li, Zhang, Han, Lye, He, Lu, Xie, Huang (CR8) 2014; 127 Rosenberg, Naicker, Winkler, Kopp (CR21) 2015; 11 (CR12) 2018; 57 Zhao, Feng, Hu, Li, Zuo, Yan, Zhang, Cao, Xu, Li, Li, Liao, Ruan, Shao, Xing (CR36) 2018; 8 Routy, Angel, Patel, Kanagaratham, Radzioch, Kema, Gilmore, Ancuta, Singer, Jenabian (CR44) 2015; 16 Goldbach-Mansky, Wilson, Fleischmann, Olsen, Silverfield, Kempf, Kivitz, Sherrer, Pucino, Csako (CR47) 2009; 151 He, Xing, Ruan, Hong, Cheng, Hu, Xin, Wei, Feng, Hsi (CR16) 2012; 7 Freiberg, Chang, Kuller, Skanderson, Lowy, Kraemer, Butt, Bidwell Goetz, Leaf, Oursler, Rimland, Rodriguez Barradas, Brown, Gibert, McGinnis, Crothers, Sico, Crane, Warner, Gottlieb, Gottdiener, Tracy, Budoff, Watson, Armah, Doebler, Bryant, Justice (CR19) 2013; 173 Teeraananchai, Kerr, Amin, Ruxrungtham, Law (CR18) 2017; 18 Tang, Mao, Tang, Han, Xu, Li (CR32) 2018; 18 CR13 Brown, Qaqish (CR23) 2006; 20 Kusunoki, Yamazaki, Kitasato, Beppu, Aoki, Kawai (CR49) 2004; 4 Ye, Zeng, Li, Zhang, Fang, Luo, Qiu, Han, Li (CR24) 2010; 53 Cao, Gong, Han, Xie, Li, Zhang, Li, Song, Zhu, Li (CR22) 2013; 18 Wang, Li, Zhang, Han, Zhang, Zhu, Li (CR30) 2012; 26 Li, Wu, Dai, Qiu, Han, Xie, Zhu, Li (CR42) 2011; 53 Zhang, Wang, Zhou, Han, Xie, Qiu, Guo, Li, Wang, Ghanem (CR6) 2013; 15 Lundgren, Babiker, Gordin, Emery, Grund, Sharma, Avihingsanon, Cooper, Fatkenheuer, Llibre (CR15) 2015; 373 Cao, Song, Li, Qiu, Xie, Han, Lyu, Wang, Fan (CR34) 2014; 53 Ma, Zhao, Yu, Bulterys, Robinson, Zhao, Dou, Chiliade, Wei, Zhang (CR39) 2010; 50 Luo, Zeng, Li, Lv, Wang, Guo, Han, Xie, Qiu, Li, Song, Zhu, Zhang, Li, Ye, He, Lu, Huang, Tang, Wang, Zhang, Gao, Lei, Wu, Sun, Bai, Li (CR20) 2014; 58 Xie, Han, Qiu, Li, Li, Song, Wang, Thio, Li (CR29) 2016; 19 Li, Xie, Li, Routy, Li, Han, Qiu, Lv, Song, Sun, Zhang, Wang, Jiang (CR48) 2015; 16 Li, Dai, Kuang, Jiang, Han, Qiu, Xie, Zuo, Li (CR5) 2008; 3 Li, Zhang, Lu, Cai, Wu, Sun, Zhao, Zhang, Cao (CR25) 2017; 165 Hong, Zhou (CR1) 1986; 25 Li, Xie, Han, Wang, Zhu, Wang, Lv, Guo, Qiu, Li (CR31) 2016; 72 Xie, Hsieh, Sun, Wang, Lv, Fan, Li (CR33) 2017; 12 Tao, Younger, Fan, Wang, Lipsky (CR45) 2002; 46 (CR27) 2019; 37 ENCORE1 Study Group: Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (478_CR9) 2014; 383 H Li (478_CR25) 2017; 165 FD Zhang (478_CR37) 2017; 12 F Guo (478_CR11) 2018; 19 Y Li (478_CR31) 2016; 72 Y Cao (478_CR22) 2013; 18 T Li (478_CR5) 2008; 3 D Carey (478_CR10) 2015; 15 MS Freiberg (478_CR19) 2013; 173 C Zhang (478_CR6) 2013; 15 AZ Rosenberg (478_CR21) 2015; 11 H Tang (478_CR32) 2018; 18 FJ Zhang (478_CR3) 2005; 15 TT Brown (478_CR23) 2006; 20 S Teeraananchai (478_CR18) 2017; 18 478_CR2 478_CR13 R Goldbach-Mansky (478_CR47) 2009; 151 J Xie (478_CR29) 2016; 19 F Zhang (478_CR4) 2007; 21 X Tao (478_CR45) 2002; 46 AIDS Professional Group (478_CR26) 2017; 10 N Kusunoki (478_CR49) 2004; 4 T Li (478_CR8) 2014; 127 H Wang (478_CR30) 2012; 26 Y Li (478_CR17) 2014; 28 T Li (478_CR48) 2015; 16 Y Hong (478_CR1) 1986; 25 W Cao (478_CR34) 2014; 53 S Zhao (478_CR36) 2018; 8 M Massanella (478_CR43) 2016; 11 X He (478_CR16) 2012; 7 Y Xu (478_CR38) 2018; 163 Y Ma (478_CR39) 2010; 50 Society of Tropical Diseases and Parasitology of Chinese Medical Association (478_CR27) 2019; 37 QW Lv (478_CR46) 2015; 74 AIDS Professional Group (478_CR14) 2015; 8 J Xie (478_CR33) 2017; 12 AIDS Professional Group (478_CR7) 2011; 29 J Wu (478_CR40) 2014; 27 J Lundgren (478_CR15) 2015; 373 F Zhang (478_CR28) 2014; 14 Y Ye (478_CR24) 2010; 53 HP Li (478_CR35) 2016; 16 AIDS and Hepatitis C Professional Group (478_CR12) 2018; 57 L Luo (478_CR20) 2014; 58 NR Klatt (478_CR41) 2013; 254 T Li (478_CR42) 2011; 53 JP Routy (478_CR44) 2015; 16 |
References_xml | – volume: 14 start-page: 1065 issue: 11 year: 2014 end-page: 1072 ident: CR28 article-title: HIV, hepatitis B virus, and hepatitis C virus co-infection in patients in the China National Free Antiretroviral Treatment Program, 2010-12: a retrospective observational cohort study publication-title: Lancet Infect Dis – volume: 53 start-page: 276 issue: 2 year: 2010 end-page: 278 ident: CR24 article-title: HIV infection: an independent risk factor of peripheral arterial disease publication-title: J Acquir Immune Defic Syndr – volume: 58 start-page: 1459 issue: 10 year: 2014 end-page: 1466 ident: CR20 article-title: Prospective echocardiographic assessment of cardiac structure and function in Chinese persons living with HIV publication-title: Clin Infect Dis – volume: 26 start-page: 1755 issue: 14 year: 2012 end-page: 1763 ident: CR30 article-title: Immunological and virological responses to cART in HIV/HBV co-infected patients from a multicenter cohort publication-title: Aids – volume: 18 start-page: 272 issue: 1 year: 2018 ident: CR32 article-title: "Late for testing, early for antiretroviral therapy, less likely to die": results from a large HIV cohort study in China, 2006-2014 publication-title: BMC Infect Dis – volume: 28 start-page: 521 issue: 4 year: 2014 end-page: 530 ident: CR17 article-title: CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission publication-title: Aids – volume: 151 start-page: 229 issue: 4 year: 2009 end-page: 240 ident: CR47 article-title: Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial publication-title: Ann Intern Med – volume: 163 start-page: 2233 issue: 8 year: 2018 end-page: 2237 ident: CR38 article-title: Characterization of HIV-1 subtypes and transmitted drug resistance among treatment-naive HIV-infected individuals in Zhejiang, China, 2014-2017 publication-title: Arch Virol – volume: 18 start-page: 256 issue: 4 year: 2017 end-page: 266 ident: CR18 article-title: Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis publication-title: HIV Med – volume: 16 start-page: 49 issue: 2 year: 2015 end-page: 56 ident: CR48 article-title: Tripterygium wilfordii Hook F extract in cART-treated HIV patients with poor immune response: a pilot study to assess its immunomodulatory effects and safety publication-title: HIV Clin Trials – volume: 383 start-page: 1474 issue: 9927 year: 2014 end-page: 1482 ident: CR9 article-title: (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial publication-title: Lancet – volume: 15 start-page: 540 issue: 62 year: 2013 end-page: 545 ident: CR6 article-title: The interaction of CD4 T-cell count and nevirapine hepatotoxicity in China: a change in national treatment guidelines may be warranted publication-title: J Acquir Immune Defic Syndr – volume: 11 start-page: 234 issue: 2 year: 2016 end-page: 241 ident: CR43 article-title: Residual inflammation and viral reservoirs: alliance against an HIV cure publication-title: Curr Opin HIV AIDS – volume: 16 start-page: 605 issue: 1 year: 2016 ident: CR35 article-title: The prevalence of drug resistance among treatment-naive HIV-1-infected individuals in China during pre- and post-2004 publication-title: BMC Infect Dis – volume: 254 start-page: 326 issue: 1 year: 2013 end-page: 342 ident: CR41 article-title: Immune activation and HIV persistence: implications for curative approaches to HIV infection publication-title: Immunol Rev – volume: 8 start-page: 12273 issue: 1 year: 2018 ident: CR36 article-title: Prevalence of transmitted HIV drug resistance in antiretroviral treatment naive newly diagnosed individuals in China publication-title: Sci Rep – volume: 29 start-page: 629 issue: 10 year: 2011 end-page: 640 ident: CR7 article-title: Society of Infectious Diseases Chinese Medical Association: guidelines for diagnosis and treatment of HIV/AIDS in China (2011) publication-title: ZHONGHUA CHUAN RAN BING ZA ZHI – volume: 27 start-page: 838 issue: 11 year: 2014 end-page: 871 ident: CR40 article-title: The prevalence of HIV drug resistance among treatment-failure individuals and treatment-naive individuals in China: a meta-analysis publication-title: Biomed Environ Sci – volume: 37 start-page: 129 issue: 3 year: 2019 end-page: 138 ident: CR27 article-title: Expert consensus on diagnosis and treatment of HIV infection combined with nontuberculosis mycobacterium infection publication-title: Chin J Infect Dis – volume: 21 start-page: S143 issue: Suppl 8(1473–5571 (Electronic)) year: 2007 end-page: S148 ident: CR4 article-title: The Chinese free antiretroviral treatment program: challenges and responses publication-title: Aids – volume: 19 start-page: 20659 issue: 1 year: 2016 ident: CR29 article-title: Prevalence of hepatitis B and C viruses in HIV-positive patients in China: a cross-sectional study publication-title: J Int AIDS Soc – volume: 20 start-page: 2165 issue: 17 year: 2006 end-page: 2174 ident: CR23 article-title: Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review publication-title: Aids – volume: 8 start-page: 385 issue: 5 year: 2015 end-page: 401 ident: CR14 article-title: Society of Infectious Diseases, Chinese Medical Association: third edition of the guidelines for diagnosis and treatment of HIV/AIDS (2015) publication-title: Chin J Clin Infect Dis – volume: 173 start-page: 614 issue: 8 year: 2013 end-page: 622 ident: CR19 article-title: HIV infection and the risk of acute myocardial infarction publication-title: JAMA Intern Med – ident: CR2 – volume: 18 start-page: 307 issue: 4 year: 2013 end-page: 312 ident: CR22 article-title: Prevalence and risk factors for chronic kidney disease among HIV-infected antiretroviral therapy-naive patients in mainland China: a multicenter cross-sectional study publication-title: Nephrology(Carlton) – volume: 4 start-page: 2 issue: 1471–2210 (Electronic) year: 2004 ident: CR49 article-title: Triptolide, an active compound identified in a traditional Chinese herb, induces apoptosis of rheumatoid synovial fibroblasts publication-title: BMC Pharmacol – volume: 10 start-page: 81 issue: 2 year: 2017 end-page: 90 ident: CR26 article-title: Society of Infectious Diseases Chinese Medical Association, Society of Tropical Diseases and Parasitology of Chinese Medical Association: expert consensus on diagnosis and treatment of HIV infection combined with mycobacterium tuberculosis infection publication-title: Chin J Clin Infect Dis – volume: 12 start-page: e0165110 issue: 2 year: 2017 ident: CR37 article-title: An analysis of drug resistance among people living with HIV/AIDS in Shanghai, China publication-title: PLoS One – volume: 74 start-page: 1078 issue: 6 year: 2015 end-page: 1086 ident: CR46 article-title: Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): a randomised, controlled clinical trial publication-title: Ann Rheum Dis – volume: 25 start-page: 436 issue: 7 year: 1986 end-page: 439 ident: CR1 article-title: Clinical pathological conference: fever, cough and progressive dyspnea publication-title: Chin J Internal Med – volume: 50 start-page: 264 issue: 2 year: 2010 end-page: 271 ident: CR39 article-title: Predictors of virologic failure in HIV-1-infected adults receiving first-line antiretroviral therapy in 8 provinces in China publication-title: Clin Infect Dis – volume: 57 start-page: 867 issue: 12 year: 2018 end-page: 884 ident: CR12 article-title: Society of Infectious Diseases Chinese Medical Association, Chinese Center for Disease Control and Prevention: [Chinese guidelines for diagnosis and treatment of HIV/AIDS (2018)] publication-title: Zhonghua Nei Ke Za Zhi – volume: 53 start-page: 944 issue: 9 year: 2011 end-page: 951 ident: CR42 article-title: Reduced thymic output is a major mechanism of immune reconstitution failure in HIV-infected patients after long-term antiretroviral therapy publication-title: Clin Infect Dis – volume: 127 start-page: 59 issue: 1 year: 2014 end-page: 65 ident: CR8 article-title: An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China publication-title: Chin Med J – volume: 46 start-page: 1735 issue: 7 year: 2002 end-page: 1743 ident: CR45 article-title: Benefit of an extract of Tripterygium Wilfordii Hook F in patients with rheumatoid arthritis: a double-blind, placebo-controlled study publication-title: Arthritis Rheum – volume: 7 start-page: e47289 issue: 10 year: 2012 ident: CR16 article-title: A comprehensive mapping of HIV-1 genotypes in various risk groups and regions across China based on a nationwide molecular epidemiologic survey publication-title: PLoS One – volume: 12 start-page: e0182335 issue: 8 year: 2017 ident: CR33 article-title: Delays in HIV diagnosis and associated factors among patients presenting with advanced disease at a tertiary care hospital in Beijing, China publication-title: PLoS One – volume: 16 start-page: 48 issue: 1 year: 2015 end-page: 56 ident: CR44 article-title: Assessment of chloroquine as a modulator of immune activation to improve CD4 recovery in immune nonresponding HIV-infected patients receiving antiretroviral therapy publication-title: HIV Med – volume: 11 start-page: 150 issue: 3 year: 2015 end-page: 160 ident: CR21 article-title: HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment publication-title: Nat Rev Nephrol – ident: CR13 – volume: 165 start-page: 578 issue: 6 year: 2017 end-page: 581 ident: CR25 article-title: Expert consensus on management of HIV infection combined with chronic renal diseases publication-title: Chin J AIDS&STD – volume: 53 start-page: 537 issue: 7 year: 2014 end-page: 541 ident: CR34 article-title: Zhou B et al: [Clinical characteristics of 297 newly diagnosed Chinese HIV/AIDS patients] publication-title: Zhonghua Nei Ke Za Zhi – volume: 3 start-page: e3918 issue: 12 year: 2008 ident: CR5 article-title: Three generic nevirapine-based antiretroviral treatments in Chinese HIV/AIDS patients: multicentric observation cohort publication-title: PLoS One – volume: 72 start-page: 39 issue: 1 year: 2016 end-page: 45 ident: CR31 article-title: Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL publication-title: J Acquir Immune Defic Syndr – volume: 19 start-page: 440 year: 2018 end-page: 450 ident: CR11 article-title: Prospective plasma efavirenz concentration assessment in Chinese HIV-infected adults enrolled in a large multicentre study publication-title: HIV Med – volume: 373 start-page: 795 issue: 9 year: 2015 end-page: 807 ident: CR15 article-title: Initiation of antiretroviral therapy in early asymptomatic HIV infection publication-title: N Engl J Med – volume: 15 start-page: 877 issue: 11–12 year: 2005 end-page: 882 ident: CR3 article-title: Current progress of China’s free ART program publication-title: Cell Res – volume: 15 start-page: 793 issue: 7 year: 2015 end-page: 802 ident: CR10 article-title: Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study publication-title: Lancet Infect Dis – volume: 173 start-page: 614 issue: 8 year: 2013 ident: 478_CR19 publication-title: JAMA Intern Med doi: 10.1001/jamainternmed.2013.3728 – volume: 10 start-page: 81 issue: 2 year: 2017 ident: 478_CR26 publication-title: Chin J Clin Infect Dis – volume: 53 start-page: 537 issue: 7 year: 2014 ident: 478_CR34 publication-title: Zhonghua Nei Ke Za Zhi – volume: 37 start-page: 129 issue: 3 year: 2019 ident: 478_CR27 publication-title: Chin J Infect Dis – volume: 151 start-page: 229 issue: 4 year: 2009 ident: 478_CR47 publication-title: Ann Intern Med doi: 10.7326/0003-4819-151-4-200908180-00005 – volume: 50 start-page: 264 issue: 2 year: 2010 ident: 478_CR39 publication-title: Clin Infect Dis doi: 10.1086/649215 – volume: 254 start-page: 326 issue: 1 year: 2013 ident: 478_CR41 publication-title: Immunol Rev doi: 10.1111/imr.12065 – volume: 11 start-page: 234 issue: 2 year: 2016 ident: 478_CR43 publication-title: Curr Opin HIV AIDS doi: 10.1097/COH.0000000000000230 – ident: 478_CR13 – volume: 165 start-page: 578 issue: 6 year: 2017 ident: 478_CR25 publication-title: Chin J AIDS&STD – volume: 16 start-page: 605 issue: 1 year: 2016 ident: 478_CR35 publication-title: BMC Infect Dis doi: 10.1186/s12879-016-1928-x – volume: 373 start-page: 795 issue: 9 year: 2015 ident: 478_CR15 publication-title: N Engl J Med doi: 10.1056/NEJMoa1506816 – volume: 57 start-page: 867 issue: 12 year: 2018 ident: 478_CR12 publication-title: Zhonghua Nei Ke Za Zhi – volume: 11 start-page: 150 issue: 3 year: 2015 ident: 478_CR21 publication-title: Nat Rev Nephrol doi: 10.1038/nrneph.2015.9 – volume: 19 start-page: 20659 issue: 1 year: 2016 ident: 478_CR29 publication-title: J Int AIDS Soc doi: 10.7448/IAS.19.1.20659 – volume: 14 start-page: 1065 issue: 11 year: 2014 ident: 478_CR28 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(14)70946-6 – volume: 53 start-page: 944 issue: 9 year: 2011 ident: 478_CR42 publication-title: Clin Infect Dis doi: 10.1093/cid/cir552 – volume: 8 start-page: 12273 issue: 1 year: 2018 ident: 478_CR36 publication-title: Sci Rep doi: 10.1038/s41598-018-29202-2 – volume: 12 start-page: e0165110 issue: 2 year: 2017 ident: 478_CR37 publication-title: PLoS One doi: 10.1371/journal.pone.0165110 – volume: 16 start-page: 48 issue: 1 year: 2015 ident: 478_CR44 publication-title: HIV Med doi: 10.1111/hiv.12171 – volume: 15 start-page: 540 issue: 62 year: 2013 ident: 478_CR6 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3182845cc7 – volume: 18 start-page: 256 issue: 4 year: 2017 ident: 478_CR18 publication-title: HIV Med doi: 10.1111/hiv.12421 – volume: 53 start-page: 276 issue: 2 year: 2010 ident: 478_CR24 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0b013e3181ba1c31 – volume: 4 start-page: 2 issue: 1471–2210 (Elec year: 2004 ident: 478_CR49 publication-title: BMC Pharmacol doi: 10.1186/1471-2210-4-2 – volume: 7 start-page: e47289 issue: 10 year: 2012 ident: 478_CR16 publication-title: PLoS One doi: 10.1371/journal.pone.0047289 – volume: 18 start-page: 272 issue: 1 year: 2018 ident: 478_CR32 publication-title: BMC Infect Dis doi: 10.1186/s12879-018-3158-x – volume: 163 start-page: 2233 issue: 8 year: 2018 ident: 478_CR38 publication-title: Arch Virol doi: 10.1007/s00705-018-3839-1 – volume: 18 start-page: 307 issue: 4 year: 2013 ident: 478_CR22 publication-title: Nephrology(Carlton) doi: 10.1111/nep.12031 – volume: 20 start-page: 2165 issue: 17 year: 2006 ident: 478_CR23 publication-title: Aids doi: 10.1097/QAD.0b013e32801022eb – volume: 16 start-page: 49 issue: 2 year: 2015 ident: 478_CR48 publication-title: HIV Clin Trials doi: 10.1179/1528433614Z.0000000005 – volume: 25 start-page: 436 issue: 7 year: 1986 ident: 478_CR1 publication-title: Chin J Internal Med – volume: 15 start-page: 877 issue: 11–12 year: 2005 ident: 478_CR3 publication-title: Cell Res doi: 10.1038/sj.cr.7290362 – volume: 8 start-page: 385 issue: 5 year: 2015 ident: 478_CR14 publication-title: Chin J Clin Infect Dis – volume: 21 start-page: S143 issue: Suppl 8(1473–55 year: 2007 ident: 478_CR4 publication-title: Aids doi: 10.1097/01.aids.0000304710.10036.2b – volume: 28 start-page: 521 issue: 4 year: 2014 ident: 478_CR17 publication-title: Aids doi: 10.1097/QAD.0000000000000125 – volume: 12 start-page: e0182335 issue: 8 year: 2017 ident: 478_CR33 publication-title: PLoS One doi: 10.1371/journal.pone.0182335 – volume: 383 start-page: 1474 issue: 9927 year: 2014 ident: 478_CR9 publication-title: Lancet doi: 10.1016/S0140-6736(13)62187-X – volume: 46 start-page: 1735 issue: 7 year: 2002 ident: 478_CR45 publication-title: Arthritis Rheum doi: 10.1002/art.10411 – volume: 58 start-page: 1459 issue: 10 year: 2014 ident: 478_CR20 publication-title: Clin Infect Dis doi: 10.1093/cid/ciu086 – volume: 26 start-page: 1755 issue: 14 year: 2012 ident: 478_CR30 publication-title: Aids doi: 10.1097/QAD.0b013e328355ced2 – volume: 127 start-page: 59 issue: 1 year: 2014 ident: 478_CR8 publication-title: Chin Med J doi: 10.3760/cma.j.issn.0366-6999.20132557 – volume: 72 start-page: 39 issue: 1 year: 2016 ident: 478_CR31 publication-title: J Acquir Immune Defic Syndr doi: 10.1097/QAI.0000000000000927 – volume: 3 start-page: e3918 issue: 12 year: 2008 ident: 478_CR5 publication-title: PLoS One doi: 10.1371/journal.pone.0003918 – volume: 15 start-page: 793 issue: 7 year: 2015 ident: 478_CR10 publication-title: Lancet Infect Dis doi: 10.1016/S1473-3099(15)70060-5 – volume: 27 start-page: 838 issue: 11 year: 2014 ident: 478_CR40 publication-title: Biomed Environ Sci – volume: 29 start-page: 629 issue: 10 year: 2011 ident: 478_CR7 publication-title: ZHONGHUA CHUAN RAN BING ZA ZHI – ident: 478_CR2 – volume: 19 start-page: 440 year: 2018 ident: 478_CR11 publication-title: HIV Med doi: 10.1111/hiv.12607 – volume: 74 start-page: 1078 issue: 6 year: 2015 ident: 478_CR46 publication-title: Ann Rheum Dis doi: 10.1136/annrheumdis-2013-204807 |
SSID | ssj0034946 |
Score | 2.527402 |
SecondaryResourceType | review_article |
Snippet | Purpose of Review
The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and... The introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and Prevention has led... Purpose of ReviewThe introduction of the National Free Antiretroviral Therapy Program (NFATP) in 2003 by the China National Center for AIDS/STD Control and... |
SourceID | pubmedcentral proquest pubmed crossref springer |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 26 |
SubjectTerms | Acquired immune deficiency syndrome AIDS Antiretroviral agents Antiretroviral drugs Antiretroviral therapy Drug therapy HIV Human immunodeficiency virus Medicine Medicine & Public Health Section Editor The Global Epidemic (SH Vermund The Global Epidemic (SH Vermund, Section Editor) Topical Collection on The Global Epidemic Toxicity |
Title | Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges |
URI | https://link.springer.com/article/10.1007/s11904-019-00478-x https://www.ncbi.nlm.nih.gov/pubmed/31939111 https://www.proquest.com/docview/2348263392 https://www.proquest.com/docview/2338999319 https://pubmed.ncbi.nlm.nih.gov/PMC6989417 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS9xAEB-sQimIVPsw1h5b6Ld2aR67yabfwqk9W2yh3hX7KextNvRQc2LuUPrXd2aT3HG1Cv0WksnmMbszs_P4DcBb1PEGtyUJF0YqLkQa8lTbgktlTegXVF1MDv2Tr_FgJD6fybO2KKzust27kKST1MtiN9RdlDGRcoI4VBwtxw1Je3ecxaMw6-Qv4a24miK0xXkkY9WWyvx7jFV1dMfGvJsq-Ve81Kmho6ew1dqPLGsYvg1rttqBxydthHwHNhs_HGvKi57B-TeUCZeT3zgYG3ZJ5QwtVZYR8kbNyBHLBsc_PmTHB6dsUjHXUfsjO527Voq2ZpTkyYY3U3ZgKZm-Zroq2Hd72fSWQPq2HUv9HEZHh8P-gLcNFrgRiZjxsVA6DgNtAusLY8aJ0b70i9QGKR6IpBRJoXxhVWEDoy2SxWFZlhSbiwOrVPQC1qtpZXeBqag0Miz02CRS4J5GRwQKGaGxoKX1lfAg6P5zblr0cWqCcZEvcZOJNznyJne8yW89eLe456rB3niQer9jX96uwzoPCbsnjtAI9ODN4jKuIAqL6MpO50RDGIMpyiIPXjbcXjwOT0akDjxIVubBgoDQuVevVJNfDqWbOnOKIPHgfTdjlq91_1fs_R_5K3gSkgPApZHvw_rsem5fo5U0G_dgI_v088thDx71437PLZE_TsgKRw |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3rS-QwEB_EAxXkON9VTyP4TYN9pG1635ZV2VVXQVfxW8mmKS5qV-wud_jX30wfK-sL_FbaafqYJPNLZuY3ALto4zUuS0IutC-5EJHLI2US7kujXTuh7GLa0O-cB61rcXLr31Y0OZQL88Z_f5A7aLEoTiLiRGwoOeLFHwJXyhS-1wya9axLLCtFJhEicO75gawSZD5uY9IIvUOW7wMk33hJC-Nz_At-VqiRNUo1L8CUyRZhplP5xRdhvtx9Y2VS0RLcX-BM8Nh_wcZYtw4lZ4hPWYP4NnJG26-s1b45aLQPr1g_Y0Ud7T_salQUUDQ5o9BO1v07YIeGQuhzprKEXZrHsqIEyldFWPJluD4-6jZbvCqrwLUIxZD3hFSB6yjtGFto3Qu1sn07iYwT4YEIUxEm0hZGJsbRyqBY4KZpSh65wDFSeiswnQ0yswZMeqn23UT1dOgLXMkoj6ggPYQIyje2FBY49X-OdcU5TqUvHuJXtmTSTYy6iQvdxP8s2Bvf81QybnwpvVmrL65GXx67xNgTeAj9LNgZX8ZxQ84QlZnBiGSIWTDCGciC1VLb48fhSY-MgAXhRD8YCxAn9-SVrH9XcHNTPU7hhBbs1z3m9bU-_4r174lvw2yr2zmLz9rnpxsw59IWQBFIvgnTw-eR-Y04adjbKgbIfzhfBqg |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3dT9swED9NIKFJEwI2tvA1T9rbZjUfTuLsrWqpWjbYNMrEW-Q6jlYBKSKtQPvruXOSlo6BtLcouTgfZ_t-9t39DuAj2niNy5KYCx1KLkTi80SZjIfSaN_NKLuYNvSPT6L-mTg6D88fZPHbaPfGJVnlNBBLUzFtXWd5a5H4hnaMoicSTnSHkiOKXMWVinXUdqJOMxcT94rNL0JczoMwknXazL_bWDZNj_Dm47DJv3yn1iT1NmC9xpKsXSl_E16YYgvWjmtv-Ra8qvbkWJVq9BouvuP8cDX-g42xYRNgzhC1sjaxcJSMNmVZf_Cr1R50T9m4YLa69hd2OrNlFU3JKOCTDW8nrGsosL5kqsjYT3NV1ZlA-bo0S_kGznqHw06f18UWuBaxmPKRkCryPaU94wqtR7FWbuhmifESPBBxLuJMusLIzHhaGRSL_DzPyU8XeUbKYBtWiklh3gGTQa5DP1MjHYcC1zcqIILIAIGDCo0rhQNe859TXTORU0GMy3TBoUy6SVE3qdVNeufAp_k91xUPx7PSe4360npMlqlPPD5RgIDQgQ_zyziayEWiCjOZkQzxDSY4LznwttL2_HF4MiDT4EC81A_mAsTUvXylGP-2jN1UpVN4sQOfmx6zeK2nv2Ln_8Tfw9qPbi_9Njj5ugsvfdoXsNHle7AyvZmZfQRP09GBHR_3dA0O7w |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Optimizing+Treatment+for+Adults+with+HIV%2FAIDS+in+China%3A+Successes+over+Two+Decades+and+Remaining+Challenges&rft.jtitle=Current+HIV%2FAIDS+reports&rft.au=Cao%2C+Wei&rft.au=Hsieh%2C+Evelyn&rft.au=Li%2C+Taisheng&rft.date=2020-02-01&rft.pub=Springer+US&rft.issn=1548-3568&rft.eissn=1548-3576&rft.volume=17&rft.issue=1&rft.spage=26&rft.epage=34&rft_id=info:doi/10.1007%2Fs11904-019-00478-x&rft_id=info%3Apmid%2F31939111&rft.externalDocID=PMC6989417 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1548-3568&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1548-3568&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1548-3568&client=summon |